Pharmacological Activation of mGlu 4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1 , 2 , 3 , 6-Tetrahydropyridine
暂无分享,去创建一个
[1] P. Jeffrey Conn,et al. Metabotropic glutamate receptors in the basal ganglia motor circuit , 2005, Nature Reviews Neuroscience.
[2] P. Conn,et al. Group III Metabotropic Glutamate-Receptor-Mediated Modulation of Excitatory Transmission in Rodent Substantia Nigra Pars Compacta Dopamine Neurons , 2005, Journal of Pharmacology and Experimental Therapeutics.
[3] Eric K. Richfield,et al. Risk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice , 2004 .
[4] Giuseppe Battaglia,et al. Endogenous Activation of mGlu5 Metabotropic Glutamate Receptors Contributes to the Development of Nigro-Striatal Damage Induced by 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in Mice , 2004, The Journal of Neuroscience.
[5] S. Duty,et al. Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine‐treated rat , 2004, British journal of pharmacology.
[6] H. Kita,et al. Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus , 2003, Neuroscience.
[7] A. Dilella,et al. Allosteric modulation of group III metabotropic glutamate receptor 4: A potential approach to Parkinson's disease treatment , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[8] P Jeffrey Conn,et al. Group III Metabotropic Glutamate Receptor-Mediated Modulation of the Striatopallidal Synapse , 2003, The Journal of Neuroscience.
[9] F. Nicoletti,et al. Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice , 2003, Neuropharmacology.
[10] M. Amalric,et al. Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism , 2002, The Journal of Neuroscience.
[11] F. Nicoletti,et al. Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective Drugs , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[12] K. Fuxe,et al. Group I mGluR antagonist AIDA protects nigral DA cells from MPTP-induced injury , 2001, Neuroreport.
[13] George Paxinos,et al. The Mouse Brain in Stereotaxic Coordinates , 2001 .
[14] Andrzej Pilc,et al. (S)-4C3HPG, a mixed group I mGlu receptor antagonist and a group II agonist, administered intrastriatally, counteracts parkinsonian-like muscle rigidity in rats , 2001, Brain Research.
[15] F. Nicoletti,et al. Molecular determinants of metabotropic glutamate receptor signaling. , 2001, Trends in pharmacological sciences.
[16] J. Cano,et al. Group II metabotropic glutamate receptor activation protects striatal dopaminergic nerve terminals against MPP+‐induced neurotoxicity along with brain‐derived neurotrophic factor induction , 2001, Journal of neurochemistry.
[17] O. Rascol. The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson’s disease , 2000, Journal of Neurology.
[18] W. Schmidt,et al. Activation of striatal group II metabotropic glutamate receptors has a differential effect on dopamine-D1 and -D2 receptor antagonist-induced hypokinesia in the rat , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.
[19] S. Duty,et al. The group II metabotropic glutamate receptor agonist, DCG‐IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine‐treated rat , 2000, British journal of pharmacology.
[20] M. L. de Ceballos,et al. In vivo effects of new inhibitors of catechol‐O‐methyl transferase , 1999, British journal of pharmacology.
[21] Andrzej Pilc,et al. LY354740, a group II metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats , 1998, Naunyn-Schmiedeberg's Archives of Pharmacology.
[22] G. Corsini,et al. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. , 1997, The Journal of pharmacology and experimental therapeutics.
[23] Atsuko Fukunaga,et al. A novel class of antagonists for metabotropic glutamate receptors, 7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylates , 1996 .
[24] R. Duvoisin,et al. The metabotropic glutamate receptors: Structure and functions , 1995, Neuropharmacology.
[25] B. Hyman,et al. Blockade of 1-methyl-4-phenylpyridinium ion (MPP+) nigral toxicity in the rat by prior decortication or MK-801 treatment: A stereological estimate of neuronal loss , 1993, Neurobiology of Aging.
[26] P. Löschmann,et al. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists , 1991, Nature.
[27] D. Graham. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. , 1978, Molecular pharmacology.
[28] Oliver H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[29] D. S. Albers,et al. Role of glutamate in neurodegeneration of dopamine neurons in several animal models of parkinsonism , 2005, Amino Acids.
[30] Andrzej Pilc,et al. The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity , 2000, Amino Acids.
[31] G. Robertson,et al. Pathophysiology of L-dopa-induced dyskinesias. , 1999, Movement Disorders.
[32] S. Przedborski,et al. Mechanisms of MPTP toxicity. , 1998, Movement disorders : official journal of the Movement Disorder Society.
[33] K. Lange,et al. Glutamatergic drugs in Parkinson's disease. , 1994, Life sciences.
[34] J. Costentin,et al. Correlation between (3H)dopamine specific uptake and (3H)GBR 12783 specific binding during the maturation of rat striatum. , 1989, Life sciences.